

## Adcetris® (brentuximab vedotin) (Intravenous)

Document Number: IC-0004

Last Review Date: 09/05/2023

Date of Origin: 02/28/2012

Dates Reviewed: 06/2012, 09/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017, 05/2017, 08/2017, 11/2017, 02/2018, 04/2018, 09/2018, 12/2018, 03/2019, 06/2019, 09/2019, 12/2019, 03/2020, 06/2020, 09/2020, 12/2020, 03/2021, 06/2021, 09/2021, 12/2021, 03/2022, 06/2022, 09/2022, 12/2022, 03/2023, 06/2023, 09/2023

### I. Length of Authorization <sup>1,5,7,15,18,21</sup>

Coverage will be provided for 6 months and may be renewed (unless otherwise specified).

- Treatment for Adult cHL post-auto HSCT, Pediatric cHL (excluding use in combination with AVEPC, AEPA or CAPDAC), Mycosis Fungoides (MF)/Sezary Syndrome (SS), and Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders has a maximum of 16 cycles.
- Treatment of previously untreated Pediatric cHL in combination with AVEPC (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide) has a maximum of 5 doses.
- Pediatric cHL as a component of AEPA (brentuximab vedotin, etoposide, prednisone, doxorubicin) has a maximum of 2 cycles (6 doses).
- Pediatric cHL as a component of CAPDAC (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine) has a maximum of 4 cycles (8 doses).
- Treatment of previously untreated Adult Stage III or IV Classical Hodgkin Lymphoma (cHL) has a maximum of 12 doses.
- Treatment of previously untreated Systemic Anaplastic Large Cell Lymphoma (sALCL) and other CD30-expressing Peripheral T-Cell Lymphomas (PTCL) has a maximum of 8 doses.
- Treatment of Breast-Implant Associated Anaplastic Large Cell Lymphoma (ALCL) has a maximum of 6 cycles as adjuvant therapy.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [NDC Unit]:

- Adcetris 50 mg single-dose vial: 6 vials every 28 days

#### B. Max Units (per dose and over time) [HCP Unit]:

Classical Hodgkin Lymphoma:

- 600 billable units every 28 days

**All other indications:**

- 200 billable units every 21 days

### III. Initial Approval Criteria <sup>1</sup>

Coverage is provided in the following conditions:

- Patient is at least 18 years of age (unless otherwise specified); **AND**

**Universal Criteria <sup>1</sup>**

- Patient has CD30-positive disease; **AND**
- Patient must not be receiving concomitant bleomycin; **AND**
- Patient does not have severe renal impairment (i.e., CrCl <30 mL/min); **AND**
- Patient does not have moderate or severe hepatic impairment (Child-Pugh B or C); **AND**

**Adult Classic Hodgkin Lymphoma (cHL) † Φ <sup>1,2,4,12-14</sup>**

- Used as single agent therapy; **AND**
  - Used as consolidation/maintenance therapy post-autologous hematopoietic stem cell transplant (auto-HSCT) in patients at high risk\* for relapse or progression † ‡; **OR**
  - Patient has relapsed disease after failure of auto-HSCT or after failure of at least 2 (two) prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates †; **OR**
  - Used as subsequent systemic therapy (if not previously used) for relapsed or refractory disease ‡; **OR**
  - Used as palliative therapy for relapsed or refractory disease in patients >60 years of age ‡; **OR**
  - Used following a complete or partial response to initial therapy with brentuximab vedotin and AVD (doxorubicin, vinblastine, and dacarbazine) in patients >60 years of age ‡; **OR**
- Used in combination with bendamustine; **AND**
  - Used as subsequent systemic therapy (if not previously used) for relapsed or refractory disease ‡; **OR**
- Used in combination with nivolumab; **AND**
  - Used as subsequent systemic therapy (if not previously used) for relapsed or refractory disease ‡; **OR**
- Used in combination with dacarbazine; **AND**
  - Used as primary treatment in patients >60 years of age with stage I-II unfavorable or stage III-IV disease ‡; **OR**
- Used in combination with ifosfamide, carboplatin, and etoposide (ICE); **AND**

- Used as subsequent systemic therapy (if not previously used) for relapsed or refractory disease ‡; **OR**
- Used in combination with doxorubicin, vinblastine, and dacarbazine (AVD); **AND**
  - Used as initial therapy for previously untreated stage III or IV disease ‡; **OR**
  - Used as initial therapy for previously untreated stage I or II unfavorable disease in patients >60 years of age ‡

*\*High risk for relapse or progression may be defined as:*

- *Refractory disease, disease relapse within 12 months, or relapse ≥12 months with extranodal disease following frontline therapy OR 2 or more of the following: remission duration <1 year, extranodal involvement, FDG-PET+ response at time of transplant, B symptoms, and/or >1 second-line/subsequent therapy regimen*

### **Pediatric Classic Hodgkin Lymphoma (cHL) † ‡ Φ 1,2,24**

- Patient is ≤ 18 years of age\*; **AND**
  - Used as re-induction or subsequent therapy (if not previously used); **AND**
    - Patient has relapsed or refractory disease; **AND**
    - Used in combination with bendamustine, nivolumab, or gemcitabine; **AND**
      - Used in patients heavily pretreated with platinum or anthracycline-based chemotherapy; **OR**
      - Used if a decrease in cardiac function is observed; **OR**
  - Used as maintenance therapy following high-dose therapy and autologous stem cell rescue (HDT/ASCR); **AND**
    - Used as a single agent for relapsed or refractory high risk disease (i.e., progressive disease, refractory disease, or relapse within 1 year of original diagnosis); **OR**
  - Used as primary therapy in patients with high risk disease\*\*; **AND**
    - Used as a component of AEPA (brentuximab vedotin, etoposide, prednisone, doxorubicin) regimen; **OR**
    - Used in combination with AVEPC (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide) †; **AND**
      - Patient is at least 2 years of age; **OR**
  - Used as additional treatment following primary treatment with AEPA regimen in patients with high risk disease\*\*; **AND**
    - Used as a component of CAPDAC (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine) regimen

*\*Pediatric Hodgkin Lymphoma may be applicable to adolescent and young adult (AYA) patients up to the age of 39 years.*

*\*\*High risk disease may be defined as: Stage IIB with bulk or E-lesions (involvement of extra-lymphatic tissue), Stage IIIA with bulk AND E-lesions, or Stage IIIB or IV disease.*

## Pediatric Aggressive Mature B-Cell Lymphomas (Primary Mediastinal Large B-Cell Lymphoma) ‡<sup>2,21</sup>

- Patient is ≤ 18 years of age\*; **AND**
- Used in combination with nivolumab or pembrolizumab; **AND**
- Used as consolidation/additional therapy if a partial response was achieved after therapy for relapsed or refractory disease

*\*Pediatric Aggressive Mature B-Cell Lymphoma may be applicable to adolescent and young adult (AYA) patients older than 18 years of age and less than 39 years of age, who are treated in the pediatric oncology setting.*

## T-Cell Lymphomas<sup>1-3,15,16</sup>

- Peripheral T-Cell Lymphomas (PTCL)
  - Used as a single agent for relapsed or refractory disease OR as initial palliative intent therapy for one of the following:
    - Systemic Anaplastic Large Cell Lymphoma (sALCL) † Φ
    - Peripheral T-Cell Lymphoma (PTCL) ‡ Φ
    - Angioimmunoblastic T-cell Lymphoma (AITL) ‡ Φ; **OR**
  - Used in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) as initial therapy for previously untreated:
    - Systemic Anaplastic Large Cell Lymphoma (sALCL) † Φ
    - Peripheral T-Cell Lymphoma (PTCL) not otherwise specified † Φ
    - Angioimmunoblastic T-cell Lymphoma (AITL) † Φ
    - Enteropathy-Associated T-cell Lymphoma (EATL) Φ, Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL), Nodal Peripheral T-cell Lymphoma with TFH phenotype (PTCL, TFH), or Follicular T-cell Lymphoma (FTCL) ‡
- Breast-Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) ‡
  - Used as adjuvant therapy as a single agent or in combination with cyclophosphamide, doxorubicin, and prednisone (CHP); **AND**
    - Patient has localized disease to the capsule, implant, or breast with residual disease following an incomplete excision or partial capsulectomy, if either node positive or radiation therapy is not feasible; **OR**
    - Patient has extended disease (stage II-IV); **OR**
  - Used as subsequent therapy for relapsed or refractory disease as a single agent
- Adult T-Cell Leukemia/Lymphoma ‡ Φ
  - Used as a single agent; **AND**
    - Used as subsequent therapy for non-responders to first-line therapy for acute or lymphoma subtypes; **OR**
  - Used in combination with cyclophosphamide, doxorubicin, and prednisone (CHP); **AND**

- Used as first-line therapy for acute or lymphoma subtypes; **OR**
- Used as continued treatment in responders to first-line therapy for acute or lymphoma subtypes; **OR**
- Used as subsequent therapy for non-responders to first-line therapy for chronic/smoldering subtype
- Extranodal NK/T-Cell Lymphomas ‡ Φ
  - Used as a single agent for relapsed or refractory disease; **AND**
  - Used following additional therapy with an alternate combination chemotherapy regimen (asparaginase-based) not previously used
- Hepatosplenic T-Cell Lymphoma ‡
  - Used as single-agent therapy; **AND**
  - Used for refractory disease as subsequent therapy after progression on 2 (two) first-line therapy regimens

### **Primary Cutaneous Lymphomas <sup>1,2,17</sup>**

- Mycosis Fungoides (MF) ‡ Φ/Sezary Syndrome (SS) ‡
  - Used as single agent systemic therapy; **AND**
    - Used as primary therapy (*excluding use in patients with stage IA disease*); **OR**
    - Used as subsequent therapy
- Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders ‡ Φ
  - Used as a single agent; **AND**
    - Patient has primary cutaneous anaplastic large cell lymphoma (pcALCL) ‡ Φ; **OR**
    - Patient has cutaneous ALCL with regional node (N1) (*excludes systemic ALCL*); **OR**
    - Patient has lymphomatoid papulosis (LyP) with extensive lesions that is relapsed or refractory to treatment options (e.g., clinical trial, observation, retreatment with primary treatment, or treatment with alternative regimen not used for primary treatment); **OR**
  - Used in combination with cyclophosphamide, doxorubicin, and prednisone (CHP); **AND**
    - Patient has cutaneous ALCL with regional node (N1) (*excludes systemic ALCL*)

### **B-Cell Lymphomas ‡ <sup>2,11</sup>**

- Diffuse Large B-Cell Lymphoma (DLBCL), HIV-Related B-Cell Lymphomas (i.e., DLBCL, primary effusion lymphoma, or HHV8-positive DLBCL, not otherwise specified), or High Grade B-Cell Lymphomas
  - Used as a single agent as subsequent therapy if no intention to proceed to transplant; **AND**
    - Used for relapsed or refractory disease >12 months after completion of first-line therapy; **OR**

- Used for primary refractory disease (partial response, no response, or progression) or relapsed disease <12 months after completion of first-line therapy\*; **OR**
- Used as alternative systemic therapy (if not previously used) for relapsed/refractory disease\*
- Monomorphic Post-Transplant Lymphoproliferative Disorders (PTLD)
  - Used as a single agent as subsequent therapy for B-cell type disease if no intention to proceed to transplant; **AND**
    - Used for relapsed or refractory disease >12 months after completion of initial treatment with chemoimmunotherapy; **OR**
    - Used for primary refractory disease (partial response, no response, or progression) or relapsed disease <12 months after completion of initial treatment with chemoimmunotherapy\*; **OR**
    - Used as alternative systemic therapy (if not previously used) for relapsed/refractory disease\*; **OR**
  - Used in combination with CHP (cyclophosphamide, doxorubicin, prednisone) for T-cell type disease

*\*Note: Only applies to patients in which there is no intention to proceed to CAR T-cell therapy.*

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ⓢ Orphan Drug

#### IV. Renewal Criteria <sup>1</sup>

Coverage may be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Disease response with treatment defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: peripheral neuropathy, anaphylaxis and infusion reactions, hematologic toxicities (thrombocytopenia, neutropenia, and anemia), serious infections, opportunistic infections, tumor lysis syndrome, hepatotoxicity, pulmonary toxicity, serious dermatologic reactions, gastrointestinal complications, uncontrolled hyperglycemia, etc.; **AND**
- Patient has been evaluated for the presence of progressive multifocal leukoencephalopathy (PML) and has been found to be negative

#### V. Dosage/Administration <sup>1,5,7,15,18-21,23</sup>

| Indication | Dose |
|------------|------|
|------------|------|

|   |  |
|---|--|
| Previously Untreated Stage III or IV Adult Classical Hodgkin Lymphoma                         | Administer 1.2 mg/kg (up to 120 mg) by intravenous infusion every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity   |
| Adult cHL post-auto HSCT, MF/SS, Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders | Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity  |
| Pediatric cHL   | <p><u>Previously untreated high risk disease in combination with AVEPC (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide)</u></p> <p>Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 5 doses</p> <p><u>Primary therapy for high risk disease as a component of AEPA (brentuximab vedotin, etoposide, prednisone, doxorubicin)</u></p> <p>Administer 1.2 mg/kg (up to 120 mg) by intravenous infusion on days 1, 8, 15 every 28 days for 2 cycles</p> <p><u>Additional treatment as a component of CAPDAC (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine)</u></p> <p>Administer 1.2 mg/kg (up to 120 mg) by intravenous infusion on days 1 and 8 every 21 days for 4 cycles</p> <p><u>All other treatment settings/regimens</u></p> <p>Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity</p> |
| Previously Untreated sALCL or Other CD30-expressing PTCL                                      | Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 6 to 8 doses  |
| Breast-Implant Associated Anaplastic Large Cell Lymphoma (ALCL)                               | <p><u>Adjuvant therapy</u></p> <p>Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until a maximum of 6 cycles, disease progression, or unacceptable toxicity</p> <p><u>Relapsed/Refractory Disease</u></p> <p>Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until disease progression or unacceptable toxicity</p>   |
| All other indications   | Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until disease progression or unacceptable toxicity   |

## VI. Billing Code/Availability Information

HCPSC Code:

### ADCETRIS® (brentuximab vedotin) Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2023, Magellan Rx Management



- J9042 – Injection, brentuximab vedotin, 1 mg; 1 billable unit = 1 mg

#### NDC:

- Adcetris 50 mg powder for injection in a single-dose vial: 51144-0050-xx

## VII. References

1. Adcetris [package insert]. Bothell, WA; Seattle Genetics, Inc; June 2023. Accessed August 2023.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for brentuximab vedotin. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed August 2023.
3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) T-Cell Lymphomas. Version 1.2023. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed August 2023.
4. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Hodgkin Lymphoma. Version 2.2023. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed August 2023.
5. Duvic M, Tetzlaff MT, Gangar P, et al. Results of a Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol 2015; 33:3759-65.
6. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014;123:3095-3100.
7. Alderuccio, JP., Desai, A., Yepes, M.M., et al. Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma. Clin Case Rep 2018; 6(4): 634-637. Doi:10.1002/ccr3.1382.
8. Fahrenbruch R, Kintzel P, Bott AM, et al. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. J Oncol Pract. 2018 Mar;14(3):e130-e136.



9. Hematology/Oncology Pharmacy Association (Updated January 2022). *Intravenous Cancer Drug Waste Issue Brief*. Retrieved from [https://www.hoparx.org/documents/65/HOPA\\_Drug\\_Waste\\_Issue\\_Brief\\_-\\_Updated\\_01.19.22\\_FINAL.pdf](https://www.hoparx.org/documents/65/HOPA_Drug_Waste_Issue_Brief_-_Updated_01.19.22_FINAL.pdf)
10. Bach PB, Conti RM, Muller RJ, et al. Overspending driven by oversized single dose vials of cancer drugs. *BMJ*. 2016 Feb 29;352:i788.
11. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) B-Cell Lymphomas. Version 5.2023. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed August 2023.
12. Connors JM, Jurczak W, Straus DJ, et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma [published correction appears in *N Engl J Med*. 2018 Mar 1;378(9):878]. *N Engl J Med*. 2018;378(4):331-344.
13. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2015;385(9980):1853-1862.
14. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol*. 2012;30(18):2183-2189.
15. Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomized, phase 3 trial. *Lancet*. 2019;393(10168):229-240.
16. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. *J Clin Oncol*. 2012;30(18):2190-2196.
17. Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomized, phase 3, multicentre trial. *Lancet*. 2017;390(10094):555-566.
18. Cole PD, McCarten KM, Pei Q, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial. *Lancet Oncol*. 2018 Sep;19(9):1229-1238. Doi: 10.1016/S1470-2045(18)30426-1. Epub 2018 Aug 16.
19. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. *Blood*. 2015 Feb 26;125(9):1394-402. Doi: 10.1182/blood-2014-09-598763. Epub 2015 Jan 8.

20. Chang VA, Wang HY, Reid EG. Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma. *Blood Adv*. 2019 Mar 12;3(5):766-768. Doi: 10.1182/bloodadvances.2018026351.
21. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Pediatric Aggressive Mature B-Cell Lymphomas. Version 1.2023. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed August 2023.
22. Zinzani PL, Pellegrini C, Chiappella A, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. *Blood*. 2017 Apr 20;129(16):2328-2330. doi: 10.1182/blood-2017-01-764258.
23. Zinzani PL, Santoro A, Gritti G, et al. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. *J Clin Oncol*. 2019 Nov 20;37(33):3081-3089. doi: 10.1200/JCO.19.01492.
24. Castellino SM, Pei Q, Parsons SK, et al. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. *N Engl J Med*. 2022 Nov 3;387(18):1649-1660. doi: 10.1056/NEJMoa2206660.

## Appendix 1 – Covered Diagnosis Codes

| ICD-10 | ICD-10 Description  |
|--------|---|
| C81.10 | Nodular sclerosis Hodgkin lymphoma, unspecified site                              |
| C81.11 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck           |
| C81.12 | Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes                     |
| C81.13 | Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes                   |
| C81.14 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb          |
| C81.15 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.16 | Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes                       |
| C81.17 | Nodular sclerosis Hodgkin lymphoma, spleen  |
| C81.18 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites                 |
| C81.19 | Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites              |
| C81.20 | Mixed cellularity Hodgkin lymphoma, unspecified site                              |
| C81.21 | Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck           |
| C81.22 | Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes                     |
| C81.23 | Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes                   |
| C81.24 | Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb          |

| ICD-10 | ICD-10 Description  |
|--------|---|
| C81.25 | Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb   |
| C81.26 | Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes                         |
| C81.27 | Mixed cellularity Hodgkin lymphoma, spleen  |
| C81.28 | Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites                   |
| C81.29 | Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites                |
| C81.30 | Lymphocyte depleted Hodgkin lymphoma, unspecified site                              |
| C81.31 | Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck           |
| C81.32 | Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes                     |
| C81.33 | Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes                   |
| C81.34 | Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb          |
| C81.35 | Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.36 | Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes                       |
| C81.37 | Lymphocyte depleted Hodgkin lymphoma, spleen  |
| C81.38 | Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites                 |
| C81.39 | Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites              |
| C81.40 | Lymphocyte-rich Hodgkin lymphoma, unspecified site                                  |
| C81.41 | Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck               |
| C81.42 | Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes                         |
| C81.43 | Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes                       |
| C81.44 | Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb              |
| C81.45 | Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb     |
| C81.46 | Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes                           |
| C81.47 | Lymphocyte-rich Hodgkin lymphoma, spleen  |
| C81.48 | Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites                     |
| C81.49 | Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites                  |
| C81.70 | Other Hodgkin lymphoma unspecified site   |
| C81.71 | Other Hodgkin lymphoma lymph nodes of head, face, and neck                          |
| C81.72 | Other Hodgkin lymphoma intrathoracic lymph nodes                                    |
| C81.73 | Other Hodgkin lymphoma intra-abdominal lymph nodes                                  |
| C81.74 | Other Hodgkin lymphoma lymph nodes of axilla and upper limb                         |
| C81.75 | Other Hodgkin lymphoma lymph nodes of inguinal region and lower limb                |
| C81.76 | Other Hodgkin lymphoma intrapelvic lymph nodes                                      |
| C81.77 | Other Hodgkin lymphoma spleen   |
| C81.78 | Other Hodgkin lymphoma lymph nodes of multiple sites                                |

| ICD-10 | ICD-10 Description   |
|--------|--|
| C81.79 | Other Hodgkin lymphoma extranodal and solid organ sites                            |
| C81.90 | Hodgkin lymphoma, unspecified, unspecified site                                    |
| C81.91 | Hodgkin lymphoma, unspecified, lymph nodes of head, face and neck                  |
| C81.92 | Hodgkin lymphoma, unspecified, intrathoracic lymph nodes                           |
| C81.93 | Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes                         |
| C81.94 | Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb                |
| C81.95 | Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb       |
| C81.96 | Hodgkin lymphoma, unspecified, intrapelvic lymph nodes                             |
| C81.97 | Hodgkin lymphoma, unspecified, spleen  |
| C81.98 | Hodgkin lymphoma, unspecified, lymph nodes of multiple sites                       |
| C81.99 | Hodgkin lymphoma, unspecified, extranodal and solid organ sites                    |
| C83.30 | Diffuse large B-cell lymphoma unspecified site                                     |
| C83.31 | Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck                 |
| C83.32 | Diffuse large B-cell lymphoma intrathoracic lymph nodes                            |
| C83.33 | Diffuse large B-cell lymphoma intra-abdominal lymph nodes                          |
| C83.34 | Diffuse large B-cell lymphoma lymph nodes of axilla and upper limb                 |
| C83.35 | Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb       |
| C83.36 | Diffuse large B-cell lymphoma intrapelvic lymph nodes                              |
| C83.37 | Diffuse large B-cell lymphoma, spleen  |
| C83.38 | Diffuse large B-cell lymphoma lymph nodes of multiple sites                        |
| C83.39 | Diffuse large B-cell lymphoma extranodal and solid organ sites                     |
| C83.80 | Other non-follicular lymphoma, unspecified site                                    |
| C83.81 | Other non-follicular lymphoma, lymph nodes of head, face and neck                  |
| C83.82 | Other non-follicular lymphoma, intrathoracic lymph nodes                           |
| C83.83 | Other non-follicular lymphoma, intra-abdominal lymph nodes                         |
| C83.84 | Other non-follicular lymphoma, lymph nodes of axilla and upper limb                |
| C83.85 | Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb       |
| C83.86 | Other non-follicular lymphoma, intrapelvic lymph nodes                             |
| C83.87 | Other non-follicular lymphoma, spleen  |
| C83.88 | Other non-follicular lymphoma, lymph nodes of multiple sites                       |
| C83.89 | Other non-follicular lymphoma, extranodal and solid organ sites                    |
| C83.90 | Non-follicular (diffuse) lymphoma, unspecified site                                |
| C83.91 | Non-follicular (diffuse) lymphoma, unspecified lymph nodes of head, face, and neck |
| C83.92 | Non-follicular (diffuse) lymphoma, unspecified intrathoracic lymph nodes           |

| ICD-10 | ICD-10 Description   |
|--------|--|
| C83.93 | Non-follicular (diffuse) lymphoma, unspecified intra-abdominal lymph nodes                   |
| C83.94 | Non-follicular (diffuse) lymphoma, unspecified lymph nodes of axilla and upper limb          |
| C83.95 | Non-follicular (diffuse) lymphoma, unspecified lymph nodes of inguinal region and lower limb |
| C83.96 | Non-follicular (diffuse) lymphoma, unspecified intrapelvic lymph nodes                       |
| C83.97 | Non-follicular (diffuse) lymphoma, unspecified spleen  |
| C83.98 | Non-follicular (diffuse) lymphoma, unspecified lymph nodes of multiple sites                 |
| C83.99 | Non-follicular (diffuse) lymphoma, unspecified extranodal and solid organ sites              |
| C84.00 | Mycosis fungoides, unspecified site  |
| C84.01 | Mycosis fungoides, lymph nodes of head, face and neck  |
| C84.02 | Mycosis fungoides, intrathoracic lymph nodes   |
| C84.03 | Mycosis fungoides, intra-abdominal lymph nodes   |
| C84.04 | Mycosis fungoides, lymph nodes of axilla and upper limb                                      |
| C84.05 | Mycosis fungoides, lymph nodes of inguinal region and lower limb                             |
| C84.06 | Mycosis fungoides, intrapelvic lymph nodes   |
| C84.07 | Mycosis fungoides, spleen  |
| C84.08 | Mycosis fungoides, lymph nodes of multiple sites   |
| C84.09 | Mycosis fungoides, extranodal and solid organ sites  |
| C84.10 | Sézary disease, unspecified site   |
| C84.11 | Sézary disease, lymph nodes of head, face, and neck  |
| C84.12 | Sézary disease, intrathoracic lymph nodes  |
| C84.13 | Sézary disease, intra-abdominal lymph nodes  |
| C84.14 | Sézary disease, lymph nodes of axilla and upper limb   |
| C84.15 | Sézary disease, lymph nodes of inguinal region and lower limb                                |
| C84.16 | Sézary disease, intrapelvic lymph nodes  |
| C84.17 | Sézary disease, spleen   |
| C84.18 | Sézary disease, lymph nodes of multiple sites  |
| C84.19 | Sézary disease, extranodal and solid organ sites   |
| C84.40 | Peripheral T-cell lymphoma, not classified, unspecified site                                 |
| C84.41 | Peripheral T-cell lymphoma, not classified, lymph nodes of head, face and neck               |
| C84.42 | Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes                        |
| C84.43 | Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes                      |
| C84.44 | Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb             |
| C84.45 | Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region of lower limb     |
| C84.46 | Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes                          |

| ICD-10 | ICD-10 Description  |
|--------|---|
| C84.47 | Peripheral T-cell lymphoma, not classified, spleen  |
| C84.48 | Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites                   |
| C84.49 | Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites                |
| C84.60 | Anaplastic large cell lymphoma, ALK-positive, unspecified site                              |
| C84.61 | Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face and neck            |
| C84.62 | Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes                     |
| C84.63 | Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes                   |
| C84.64 | Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb          |
| C84.65 | Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb |
| C84.66 | Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes                       |
| C84.67 | Anaplastic large cell lymphoma, ALK-positive, spleen  |
| C84.68 | Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites                 |
| C84.69 | Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites              |
| C84.7A | Anaplastic large cell lymphoma, ALK-negative, breast  |
| C84.70 | Anaplastic large cell lymphoma, ALK-negative, unspecified site                              |
| C84.71 | Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face and neck            |
| C84.72 | Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes                     |
| C84.73 | Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes                   |
| C84.74 | Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb          |
| C84.75 | Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb |
| C84.76 | Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes                       |
| C84.77 | Anaplastic large cell lymphoma, ALK-negative, spleen  |
| C84.78 | Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites                 |
| C84.79 | Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites              |
| C84.90 | Mature T/NK-cell lymphomas, unspecified site  |
| C84.91 | Mature T/NK-cell lymphomas, lymph nodes of head, face, and neck                             |
| C84.92 | Mature T/NK-cell lymphomas, intrathoracic lymph nodes                                       |
| C84.93 | Mature T/NK-cell lymphomas, intra-abdominal lymph nodes                                     |
| C84.94 | Mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb                            |
| C84.95 | Mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb                   |
| C84.96 | Mature T/NK-cell lymphomas, intrapelvic lymph nodes   |
| C84.97 | Mature T/NK-cell lymphomas, spleen  |
| C84.98 | Mature T/NK-cell lymphomas, lymph nodes of multiple sites                                   |
| C84.99 | Mature T/NK-cell lymphomas, extranodal and solid organ sites                                |



| ICD-10 | ICD-10 Description  |
|--------|---|
| C84.Z0 | Other mature T/NK-cell lymphomas, unspecified site  |
| C84.Z1 | Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck                     |
| C84.Z2 | Other mature T/NK-cell lymphomas, intrathoracic lymph nodes                               |
| C84.Z3 | Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes                             |
| C84.Z4 | Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb                    |
| C84.Z5 | Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb           |
| C84.Z6 | Other mature T/NK-cell lymphomas, intrapelvic lymph nodes                                 |
| C84.Z7 | Other mature T/NK-cell lymphomas, spleen  |
| C84.Z8 | Other mature T/NK-cell lymphomas, lymph nodes of multiple sites                           |
| C84.Z9 | Other mature T/NK-cell lymphomas, extranodal and solid organ sites                        |
| C85.10 | Unspecified B-cell lymphoma unspecified site  |
| C85.11 | Unspecified B-cell lymphoma lymph nodes of head, face, and neck                           |
| C85.12 | Unspecified B-cell lymphoma intrathoracic lymph nodes                                     |
| C85.13 | Unspecified B-cell lymphoma intra-abdominal lymph nodes                                   |
| C85.14 | Unspecified B-cell lymphoma lymph nodes of axilla and upper limb                          |
| C85.15 | Unspecified B-cell lymphoma lymph nodes of inguinal region and lower limb                 |
| C85.16 | Unspecified B-cell lymphoma intrapelvic lymph nodes                                       |
| C85.17 | Unspecified B-cell lymphoma spleen  |
| C85.18 | Unspecified B-cell lymphoma lymph nodes of multiple sites                                 |
| C85.19 | Unspecified B-cell lymphoma extranodal and solid organ sites                              |
| C85.20 | Mediastinal (thymic) large B-cell lymphoma, unspecified site                              |
| C85.21 | Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face and neck            |
| C85.22 | Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes                     |
| C85.23 | Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes                   |
| C85.24 | Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb          |
| C85.25 | Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C85.26 | Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes                       |
| C85.27 | Mediastinal (thymic) large B-cell lymphoma, spleen  |
| C85.28 | Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites                 |
| C85.29 | Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites              |
| C85.80 | Other specified types of non-Hodgkin lymphoma, unspecified site                           |
| C85.81 | Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face and neck         |
| C85.82 | Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes                  |
| C85.83 | Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes                |



| ICD-10 | ICD-10 Description  |
|--------|---|
| C85.84 | Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb         |
| C85.85 | Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region of lower limb |
| C85.86 | Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes                      |
| C85.87 | Other specified types of non-Hodgkin lymphoma, spleen                                       |
| C85.88 | Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites                |
| C85.89 | Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites             |
| C86.0  | Extranodal NK/T-cell lymphoma, nasal type   |
| C86.1  | Hepatosplenic T-cell lymphoma   |
| C86.2  | Enteropathy-type (intestinal) T-cell lymphoma   |
| C86.5  | Angioimmunoblastic T-cell lymphoma  |
| C86.6  | Primary cutaneous CD30-positive T-cell proliferations                                       |
| C91.50 | Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission            |
| C91.51 | Adult T-cell lymphoma/leukemia (HTLV-1-associated) in remission                             |
| C91.52 | Adult T-cell lymphoma/leukemia (HTLV-1-associated) in relapse                               |
| D47.Z1 | Post-transplant lymphoproliferative disorder (PTLD)   |
| Z85.71 | Personal history of Hodgkin lymphoma  |

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

| Medicare Part B Administrative Contractor (MAC) Jurisdictions |  |   |
|---|--|---|
| Jurisdiction  | Applicable State/US Territory          | Contractor  |
| E (1)   | CA, HI, NV, AS, GU, CNMI               | Noridian Healthcare Solutions, LLC                |
| F (2 & 3)   | AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ | Noridian Healthcare Solutions, LLC                |
| 5   | KS, NE, IA, MO                         | Wisconsin Physicians Service Insurance Corp (WPS) |
| 6   | MN, WI, IL                             | National Government Services, Inc. (NGS)          |
| H (4 & 7)   | LA, AR, MS, TX, OK, CO, NM             | Novitas Solutions, Inc.                           |
| 8   | MI, IN                                 | Wisconsin Physicians Service Insurance Corp (WPS) |
| N (9)   | FL, PR, VI                             | First Coast Service Options, Inc.                 |
| J (10)  | TN, GA, AL                             | Palmetto GBA, LLC                                 |

| Medicare Part B Administrative Contractor (MAC) Jurisdictions |   |  |
|---|---|--|
| Jurisdiction  | Applicable State/US Territory   | Contractor                               |
| M (11)  | NC, SC, WV, VA (excluding below)  | Palmetto GBA, LLC                        |
| L (12)  | DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA) | Novitas Solutions, Inc.                  |
| K (13 & 14)   | NY, CT, MA, RI, VT, ME, NH  | National Government Services, Inc. (NGS) |
| 15  | KY, OH  | CGS Administrators, LLC                  |

## PreferredOne Community Health Plan Nondiscrimination Notice

PreferredOne Community Health Plan (“PCHP”) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. PCHP does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

PCHP:

Provides free aids and services to people with disabilities to communicate effectively with us, such as:

- Qualified sign language interpreters
- Written information in other formats (large print, audio, accessible electronic formats, other formats)

Provides free language services to people whose primary language is not English, such as:

- Qualified interpreters
- Information written in other languages

If you need these services, contact a Grievance Specialist.

If you believe that PCHP has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:

Grievance Specialist  
PreferredOne Community Health Plan  
PO Box 59052  
Minneapolis, MN 55459-0052  
Phone: 1.800.940.5049 (TTY: 763.847.4013)  
Fax: 763.847.4010  
[customerservice@preferredone.com](mailto:customerservice@preferredone.com)

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, a Grievance Specialist is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services  
200 Independence Avenue, SW  
Room 509F, HHH Building  
Washington, D.C. 20201  
1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

## Language Assistance Services

ATTENTION: If you do not speak English, language assistance services, free of charge, are available to you. Call 1.800.940.5049 (TTY: 763.847.4013).

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.800.940.5049 (TTY: 763.847.4013).

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1.800.940.5049 (TTY: 763.847.4013).

XIYYEEFFANNAA: Afaan dubbattu Oroomiffa, taiaajiila qarqaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 1.800.940.5049 (TTY: 763.847.4013).

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1.800.940.5049 (TTY: 763.847.4013).

注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1.800.940.5049 (TTY: 763.847.4013)。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1.800.940.5049 (телетайп: 763.847.4013).

ໂບດຊາບ: ຖ້າວ່າທ່ານເວົ້າພາສາລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສຍຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທ 1.800.940.5049 (TTY: 763.847.4013).

ማስታወሻ፡ የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም እርዳታ ድርጅቶች፡ በነጻ ሊያግዝዎት ተዘጋጅተዋል፡ ወደ ሚከተለው ቁጥር ይደውሉ 1.800.940.5049 (መስማት ለተሳናቸው፡ 763.847.4013 ) .

ဟ်သုာ်ဟ်သး- နမာ်ကတိ၊ ကညီ ကိာ်အယံ၊ နမာ် ကိာ်အတၢ်မၤစၢၤလၢ တလၢာ်ဘၣ်လၢာ်စၢၤ နီတမံၤဘၣ်သန့လီၤ. ကိး 1.800.940.5049 (TTY: 763.847.4013).

**ACHTUNG:** Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1.800.940.5049 (TTY: 763.847.4013).

ប្រយ័ត្ន៖ បើសិនជាអ្នកនិយាយ ភាសាខ្មែរ, សេវាជំនួយផ្នែកភាសា ដោយមិនគិតល្បួល គឺអាចមានសំរាប់បំរើអ្នក។ ចរ ទូរស័ព្ទ 1.800.940.5049 (TTY: 763.847.4013)។

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 1.800.940.5049 (رقم هاتف الصم والبكم: 763.847.4013).

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1.800.940.5049 (TTY: 763.847.4013).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1.800.940.5049 (TTY: 763.847.4013), 번으로 전화해 주십시오.

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1.800.940.5049 (TTY: 763.847.4013).

## PreferredOne Insurance Company Nondiscrimination Notice

PreferredOne Insurance Company ("PIC") complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. PIC does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

PIC:

Provides free aids and services to people with disabilities to communicate effectively with us, such as:

- Qualified sign language interpreters
- Written information in other formats (large print, audio, accessible electronic formats, other formats)

Provides free language services to people whose primary language is not English, such as:

- Qualified interpreters
- Information written in other languages

If you need these services, contact a Grievance Specialist.

If you believe that PIC has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:

Grievance Specialist  
PreferredOne Insurance Company  
PO Box 59212  
Minneapolis, MN 55459-0212  
Phone: 1.800.940.5049 (TTY: 763.847.4013)  
Fax: 763.847.4010  
[customerservice@preferredone.com](mailto:customerservice@preferredone.com)

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, a Grievance Specialist is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services  
200 Independence Avenue, SW  
Room 509F, HHH Building  
Washington, D.C. 20201  
1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

## Language Assistance Services

ATTENTION: If you do not speak English, language assistance services, free of charge, are available to you. Call 1.800.940.5049 (TTY: 763.847.4013).

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.800.940.5049 (TTY: 763.847.4013).

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1.800.940.5049 (TTY: 763.847.4013).

XIYEEFFANNAA: Afaan dubbattu Oroomiffa, tajaajila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 1.800.940.5049 (TTY: 763.847.4013).

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1.800.940.5049 (TTY: 763.847.4013).

注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1.800.940.5049 (TTY: 763.847.4013)。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1.800.940.5049 (телетайп: 763.847.4013).

បំពេញ: ប្រសិនបើ អ្នកនិយាយភាសាខ្មែរ, សេវាជំនួយភាសា ដោយមិនគិតថ្លៃ គឺអាចមានសំរាប់អ្នក។ ហៅ 1.800.940.5049 (TTY: 763.847.4013).

ማስታወሻ: የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም እርዳታ ድርጅቶች፡ በነጻ ሊያገኙበት ተዘጋጅተዋል፡ ወደ ሚከተለው ቁጥር ይደውሉ 1.800.940.5049 (መስማት ለተሳናቸው: 763.847.4013) .

ဟံသာဝတီ: နမူနာတို့ ကညီ ကျိအသိ, နမူနာ ကျိအတိအကျတို့ တလက်ကွက်လက်စွာ နှိတ်မိသည့်သို့လိ။ ကိ: 1.800.940.5049 (TTY: 763.847.4013).

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1.800.940.5049 (TTY: 763.847.4013).

ប្រយ័ត្ន: បើសិនជាអ្នកនិយាយភាសាខ្មែរ, សេវាជំនួយភាសា ដោយមិនគិតថ្លៃ គឺអាចមានសំរាប់អ្នក។ ហៅ 1.800.940.5049 (TTY: 763.847.4013).

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 1.800.940.5049 (رقم هاتف الصم والبكم: 763.847.4013).

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1.800.940.5049 (TTY: 763.847.4013).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1.800.940.5049 (TTY: 763.847.4013). 번으로 전화해 주십시오.

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1.800.940.5049 (TTY: 763.847.4013).